Stay updated with breaking news from Real World Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was... | May 9, 2023
Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was further
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared to afliberceptMore Vabysmo patients showed an absence of blood vessel leakage
Research and Innovation Department together with Thammasat University Research and Consulting Institute (TU RAC)